Immunoassay Market Summary

The global immunoassay market size was estimated at USD 26.83 billion in 2024 and is projected to reach USD 35.10 billion by 2030, growing at a CAGR of 4.59% from 2025 to 2030. Immunoassay play an essential role in supporting personalized medicine by helping identify biomarkers that indicate how individual patients may respond to specific treatments. This enables clinicians to select therapies that are better suited to each patient’s genetic and biological profile.

The rising prevalence of cancer, cardiovascular disorders, and autoimmune diseases has significantly increased the demand for targeted therapeutic approaches. Immunoassay assist in determining which treatments are most likely to be effective, thereby reducing unwanted side effects and improving overall treatment outcomes. This transition from generalized treatment strategies to a more patient-specific approach is one of the main factors driving market expansion. Furthermore, pharmaceutical companies are increasingly integrating immunoassay into their drug development processes to enhance the accuracy, predictability, and efficiency of new therapeutic candidates, further boosting market growth.

Key Market Trends & Insights

• North America immunoassay market held the largest revenue share at 47.43 percent in 2024, driven by strong healthcare infrastructure, high diagnostic testing volumes, and increased adoption of advanced clinical technologies.
• Asia Pacific is set to record the fastest CAGR, supported by rising healthcare expenditure, expanding diagnostic capabilities, and growing awareness of early disease detection.
• Based on product, in 2024, kits and reagents led the market with a 66.10 percent share due to their high usage in routine testing, research activities, and clinical diagnostics.
• Based on application, the infectious disease segment in the immunoassay industry led the market with a 66.10 percent share and is expected to grow at a CAGR of 5.43 percent over the forecast period, reflecting the ongoing need for accurate and rapid infectious disease detection.
• In terms of technology, enzyme immunoassays secured the dominant market share of 63.90 percent in 2024, supported by their high sensitivity, reliability, and versatility across various diagnostic applications.

Order a free sample PDF of the Immunoassay Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 26.83 Billion
• 2030 Projected Market Size: USD 35.10 Billion
• CAGR (2025-2030): 4.59%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

The following are the leading companies in the immunoassay market. These companies collectively hold the largest market share and dictate industry trends.

Key Players

• Abbott
• Siemens Healthineers
• Danaher Corporation (Beckman Coulter)
• bioMérieux SA
• Quidel Corporation
• Sysmex Corporation
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche AG
• Becton, Dickinson, and Company
• Thermo Fisher Scientific, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The immunoassay market is poised for steady growth as personalized medicine becomes increasingly important in modern healthcare. Rising cases of chronic and infectious diseases, combined with the need for precise diagnostic tools, will continue to drive demand for immunoassay across clinical, research, and pharmaceutical sectors. Advancements in assay technology and expanding applications in drug development will further support market expansion. While North America maintains a strong leadership position, Asia Pacific is emerging as a fast-growing region with improving healthcare infrastructure. Companies offering highly accurate, efficient, and adaptable immunoassay solutions will be well positioned to capitalize on the market’s evolving opportunities.